Survival Bump With EGFR Inhibitor for KRAS Wild-Type Pancreatic Cancer

(MedPage Today) -- CHICAGO -- Adding an EGFR inhibitor to chemotherapy significantly improved overall survival (OS) in advanced KRAS wild-type pancreatic cancer, a randomized trial showed. Median OS improved from 8.5 months with gemcitabine...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news